Article

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

2021-02-08

Abstract excerpt

There is no effective therapy for patients with malignant pleural mesothelioma (MPM) who progressed to platinum-based chemotherapy and immunotherapy. Here, we investigate the antitumor activity of CDK4/6 inhibitors using in vitro and in vivo preclinical models of MPM. Based on publicly available transcriptomic data of MPM, patients with CDK4 or CDK6 overexpression had shorter overall survival. Treatment with a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9281afbc-2eb7-58a6-8e00-b32bfc8b978f
DOI: 10.1101/2021.02.08.430196

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaDOI 10.1101/2021.02.08.430196Read

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read

Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant MesotheliomaSemantic proximity Read

CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural MesotheliomaSemantic proximity Read

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read

microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesotheliomaSemantic proximity Read

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNASemantic proximity Read

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic ResponseSemantic proximity Read

Targeting the epigenome in malignant pleural mesotheliomaSemantic proximity Read

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionSemantic proximity Read

Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1Semantic proximity Read

The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)Semantic proximity Read

Isolated <i>BAP1</i> loss in malignant pleural mesothelioma predicts immunogenicity with implications for immunotherapeutic responseSemantic proximity Read